1. Introduction {#sec1}
===============

Losartan (LOS), 2-n-butyl-4-chloro-5-hydroxy methyl-1-\[2′-(1H-tetrazol-5-yl) (biphenyl-4-yl) methyl\] imidazole, potassium is a strong nonpeptide antihypertensive agent which exerts its action by specific blocking of angiotensin II receptors \[[@B1]\]. It has a gradual long-lasting effect as an antihypertensive. Amlodipine (AML), 3-ethyl 5-methyl (RS) 2-(2-aminoethoxymethyl)-4-(2-Chlorophenyl)-6-methyl-dihydropyridine-3,5-dicarboxylate is a calcium channel blocker which inhibits the influx of extracellular calcium across the myocardial and vascular muscle cell membranes \[[@B2]\]. Hydrochlorothiazide (HCZ), 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide, which is widely used in antihypertensive pharmaceutical preparations reduces active sodium reabsorption and peripheral vascular resistance \[[@B1]--[@B3]\].

A literature survey reveals that a variety of spectrophotometric and chromatographic methods, including UV derivative, the simultaneous equation method, colorimetric determination, HPLC, ratio derivative and compensation technique, and a stability indicating HPLC method, have been reported for the determination of LOS in pharmaceutical dosage forms in combination with other drugs \[[@B4]--[@B14]\]. Spectrophotometric and chromatographic methods have been reported for determination of AML, in combination with other drugs, in bulk and pharmaceutical dosage forms \[[@B15]--[@B24]\]. A variety of methods have been used for the determination of hydrochlorothiazide \[[@B25]--[@B34]\]. No method has been reported for the simultaneous estimation of LOS, AML, and HCZ in the combined dosage form.

In recent years TLC has been improved to incorporate HPTLC-grade stationary phases, automated sample-application devices, a controlled development environment, automated development, forced-flow techniques, computer-controlled densitometry, quantitation, and fully validated procedures. These features result in methods which are not only convenient, rapid, robust, and cost effective but also reproducible, accurate, and reliable. The objective of this investigation was, therefore, to establish an HPTLC method for simultaneous estimation of LOS, AML, and HCZ in bulk and in tablets.

2. Experimental {#sec2}
===============

2.1. Materials and Reagents {#sec2.1}
---------------------------

Analytically pure samples of losartan potassium, hydrochlorothiazide, and amlodipine besylate were procured from Madras Pharmaceuticals, Chennai, as gift samples and used as working standards, methanol of HPLC grade from Merck (Mumbai, India), and chloroform, acetone, and formic acid of analytical reagent grade from S.D. Fine Chemicals were used, without purification to prepare the mobile phase.

A solution containing 1 mg/mL losartan potassium, amlodipine besylate, and hydrochlorothiazide was prepared by dissolving 10 mg of each standard in 10 mL methanol and was used as working standard solution.

2.2. Sample Preparation {#sec2.2}
-----------------------

Twenty TRILOPACE\* tablets by Akums Drugs & Pharmaceuticals Ltd containing 50 mg losartan potassium, 5 mg amlodipine besylate, and 12.5 mg hydrochlorothiazide were weighed and powdered. An amount of powder equivalent to 50 mg of LOS, 5 mg of AML, and 12.5 mg of HCZ was transferred to a 50 mL volumetric flask. After addition of 30 mL of methanol and sonication (30 min), the solution was diluted to volume with the same solvent and filtered through a 0.45 *μ* filter (Millipore, Milford, MA, USA). To this solution known amount of amlodipine standard (20 mg) was added (standard addition method) as its content is very low in the formulation. This solution (1.0, 2.0, and 3.0 *μ*L containing 1000, 2000, and 3000 ng/spot of LOS, 500, 1000, and 1500 ng/spot of AML, and 250, 500, and 750 ng/spot of HCZ) was used for assay of losartan potassium, amlodipine, and hydrochlorothiazide in the tablets.

2.3. Chromatography {#sec2.3}
-------------------

Chromatography was performed on 10 cm × 10 cm aluminium HPTLC plates coated with 0.2 mm layers of silica gel 60 F~254~ (Merck). Samples were applied as 6 mm bands by means of a CAMAG (Muttenz Switzerland) Linomat V automatic sample applicator equipped with a 100 *μ*L syringe (Hamilton, Reno, Nevada, USA). The distance between the bands of 14.0 mm and the spraying rate of 50 nl per second were maintained. Ascending development of the plate up to a distance of 85 mm was performed at 25 ± 2°C, with chloroform-methanol-acetone-formic acid 7.5 : 1.3 : 0.5 : 0.03 (*v*/*v*/*v*/*v*) as mobile phase. The development was carried out in a CAMAG twin-trough chamber previously saturated with mobile phase vapour for 20 min. The average development time was 30 min. Densitometric scanning at 254 nm was performed with a CAMAG TLC scanner 3 equipped with CAMAG Wincats software version 1.4.4 using deuterium light source. During scanning process, the slit dimensions were fixed at 4.00 mm × 0.30 mm.

3. Results and Discussion {#sec3}
=========================

3.1. Validation of the Method {#sec3.1}
-----------------------------

The method was validated in accordance with ICH guidelines \[[@B35]\].

### 3.1.1. Linearity {#sec3.1.1}

Different aliquots of standard solution equivalent to 0.5--3 *μ*g of LOS, AML, and HCZ per band were applied on the precoated TLC plates. The plates were then developed, dried, and scanned as described above. Calibration plots were constructed by plotting peak areas against the corresponding concentration of drugs (ng per spot). For all three drugs, the detector response was found to be a linear function of amount in the range 500--3000 ng per spot. The correlation coefficients of all the three drugs were found to be 0.9988 for LOS, 0.9985 for AML, and 0.9990 for HCZ, respectively. The average linear regression equations were *Y* = 4571.56*X* + 416.48  for LOS, *Y* = 3229.40*X* + 300.24 for AML, and *Y* = 5917.03*X* + 422.70  for HCZ.

### 3.1.2. Sensitivity {#sec3.1.2}

The sensitivity of measurement of LOS, AML, and HCZ was estimated in terms of the limit of quantitation (LOQ). The smallest amount of each drug was also detected under the chromatographic conditions in terms of the limit of detection (LOD). LOQ and LOD were calculated by use of the equations LOD = 3 × *N*/*B* and LOQ = 10 × *N*/*B*, where *N* is the standard deviation of the peak areas of the drugs, taken as a measure of the noise and *B* is the slope of the corresponding calibration plot. LOQ and LOD for losartan potassium were found to be 0.382 and 0.121 *μ*g/spot, respectively. For amlodipine they were 0.584 and 0.188 *μ*g/spot, respectively, and for hydrochlorothiazide they were 0.497 and 0.162 *μ*g/spot, respectively.

3.2. Evaluation of Precision for Assay of the Pharmaceutical Preparation {#sec3.2}
------------------------------------------------------------------------

The amount of losartan potassium, amlodipine, and hydrochlorothiazide in the pharmaceutical preparation were determined by replicate analysis (*n* = 3). The results are reported in [Table 1](#tab1){ref-type="table"}.

Precision was determined by analysis of standard solutions containing concentrations of LOS, AML, and HCZ covering the entire calibration range. The precision of the method as intraday variation (CV, %) was determined by analysis of these solutions three times on the same day. Interday precision (CV, %) was assessed by analysis of these solutions on three different days over a period of one week. The results of the precision studies are shown in [Table 2](#tab2){ref-type="table"}.

### 3.2.1. Accuracy {#sec3.2.1}

An accuracy of the method was determined by analysis of standard additions at three different levels, that is, multiple-level recovery studies. The preanalyzed sample solution (2, 0.5, and 0.2 *μ*g/mL of LOS, HCZ, and AML) was spiked with amounts equivalent to 80, 100, and 120% of standard drugs. These solutions were reanalysed, and the recoveries were found to be within the acceptable limits ([Table 3](#tab3){ref-type="table"}).

### 3.2.2. Specificity {#sec3.2.2}

The mobile phase used was found to be effective in resolving the drugs ([Figure 1](#fig1){ref-type="fig"}). The *R* ~*F*~ values of losartan potassium, amlodipine, and hydrochlorothiazide were 0.74, 0.35, and 0.57, respectively. Typical overlaid absorption spectra of LOS, AML, and HCZ is shown in [Figure 2](#fig2){ref-type="fig"}. Peak purity of the drugs was tested by acquiring spectra at the peak start (*S*), peak apex (*A*), and peak end (*E*) positions. Results from correlation of the spectra were for losartan potassium *r*(*S*, *M*) = 0.9996 and *r*(*M*, *E*) = 0.9994, for amlodipine *r*(*S*, *M*) = 0.9994 and *r*(*M*, *E*) = 0.9996, and for hydrochlorothiazide *r*(*S*, *M*) = 0.9998 and *r*(*M*, *E*) = 0.9997. The results of peak purity ensure the specificity and can conclude that no impurities or degradation products were coeluted.

### 3.2.3. Repeatability {#sec3.2.3}

The repeatability of sample preparation was assessed by application of 2 *μ*L standard drug solution six times on a HPTLC plate. After development of plate, peak height and peak area were recorded for the zones. The CV (%) of peak height and area were calculated and found to be 0.45 and 0.56, respectively, for LOS, 0.34 and 0.43 for AML, and 0.67 and 0.32 for HCZ.

4. Conclusion {#sec4}
=============

The proposed HPTLC method for simultaneous analysis of losartan potassium, amlodipine, and hydrochlorothiazide in pharmaceutical dosage forms has been established for the first time. Use of HPTLC enables analysis of several samples at the same time. The method is very simple, rapid, and provides accurate and precise results.

The authors express their gratitude to the Madras Pharmaceuticals Ltd, Chennai, for the generous gifts of pure samples of losartan potassium, amlodipine besylate, and hydrochlorothiazide. The authors thank the management for providing the facilities to carry out the work.

![Typical densitogram obtained from losartan potassium (*R* ~*F*~ = 0.74), amlodipine besylate (*R* ~*F*~ = 0.35), and hydrochlorothiazide (*R* ~*F*~ = 0.57). Detection was at 254 nm and the mobile phase was chloroform : methanol : acetone : formic acid 7.5 : 1.3 : 0.5 : 0.03 (*v*/*v*/*v*/*v*).](JAMC2012-108281.001){#fig1}

![Typical absorption spectra of losartan potassium, amlodipine besylate, and hydrochlorothiazide.](JAMC2012-108281.002){#fig2}

###### 

Results from assay of losartan potassium, amlodipine besylate, and hydrochlorothiazide in Trilopace\*H tablets.

  Component             Label claim (mg)   Amount found (mg ± SD, *n* = 3)   Percentage of label claim (±SD)
  --------------------- ------------------ --------------------------------- ---------------------------------
  Losartan potassium    50                 49.51 ± 0.330                     99.03 ± 0.665
  Amlodipine besylate   5                  4.86 ± 0.057                      98.47 ± 1.114
  Hydrochlorothiazide   12.5               12.4 ± 0.036                      99.22 ± 0.284

###### 

Results from evaluation of precision.

  ---------------------------------------------------------------------------------------------------------------
  Drug                  Concentration (ng per spot)   Intraday precision (CV, %, *n* = 3)   Interday precision\
                                                                                            (CV, %, *n* = 3)
  --------------------- ----------------------------- ------------------------------------- ---------------------
  Losartan potassium    1000                          0.345                                 0.386

  2000                  0.523                         0.563                                 

  3000                  0.213                         0.254                                 

                                                                                            

  Amlodipine besylate   500                           0.324                                 0.382

  1000                  0.651                         0.685                                 

  1500                  0.772                         0.791                                 

                                                                                            

  Hydrochlorothiazide   500                           0.821                                 0.882

  1500                  0.631                         0.653                                 

  2500                  0.812                         0.876                                 
  ---------------------------------------------------------------------------------------------------------------

###### 

Results from recovery studies.

  Brand name                      Drug                         Recovery level (%)   Initial amount (ng)   Amount added (ng)   Recovery (%)   CV (%)
  ------------------------------- ---------------------------- -------------------- --------------------- ------------------- -------------- --------
  Trilopace\*H                    Losartan potassium (50 mg)   80                   2000                  1600                100.56         0.213
  100                             2000                         2000                 99.43                 0.321                              
  120                             2000                         2400                 99.67                 0.422                              
  Amlodipine besylate (5 mg)      80                           200                  160                   100.58              0.616          
  100                             200                          200                  101.12                0.222                              
  120                             200                          240                  99.85                 0.414                              
  Hydrochlorothiazide (12.5 mg)   80                           500                  400                   99.43               0.552          
  100                             500                          500                  99.21                 0.608                              
  120                             500                          600                  100.63                0.621                              

[^1]: Academic Editor: Peter Stockwell
